What is Gland Pharma Limited's latest revenue?

Gland Pharma Limited reported revenue of ₹6,431 Cr in its latest annual results, per the filed results.

What is Gland Pharma Limited's latest net profit?

Gland Pharma Limited reported net profit of ₹1,027 Cr in its latest annual results, per the filed results.

What is Gland Pharma Limited's return on equity?

Gland Pharma Limited posted ROE of 10.9% and ROCE of 15.7% for its latest annual results, computed from filed statements.

What is Gland Pharma Limited's operating margin?

Gland Pharma Limited's operating margin was 23.3% in its latest annual results, derived from filed operating expenses.

How much did Gland Pharma Limited's revenue grow year-on-year?

Gland Pharma Limited's revenue changed 14.5% year-on-year in its latest annual results, per the filed results.

GLA

GLAND

Name: Gland Pharma Limited (GLAND) quarterly results & financial statements
Creator: Upmazing

Gland Pharma Limited

HealthcareNIFTY Smallcap 250

ISIN INE068V01023

—

Day

52W

MCap₹48,373 Cr

goodUpmazing Score

Open chart ↗

GLA

GLAND

Gland Pharma Limited

HealthcareNIFTY Smallcap 250

ISIN INE068V01023

—

Day

52W

MCap₹48,373 Cr

goodUpmazing Score

Open chart ↗

Gland Pharma Limited (GLAND) reported revenue of ₹1,800 Cr and net profit of ₹317 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.

GLAND fundamentals, Fundamental score 72/100

The statements below are read from Gland Pharma Limited’s filed results, 25 filed quarters and 7 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.

Latest: Q1 FY26-27 · filed Aug 11, 2026 · audited

Sales CAGR · 3Y+21.1%FY22 → FY25

Sales CAGR · 4Y+9.9%FY21 → FY25

PAT CAGR · 3Y+9.6%FY22 → FY25

PAT CAGR · 4Y−4.0%FY21 → FY25

Price · 1Y+55.5%EOD

Price CAGR · 3Y+20.2%EOD

Quarterly resultsConsolidated

₹ Cr	Jun2020	Sep2020	Dec2020	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026Latest	YoYlatest
Sales	884	832	859	888	1,154	1,081	1,063	1,103	857	1,044	938	785	1,209	1,373	1,545	1,537	1,402	1,406	1,384	1,425	1,506	1,487	1,695	1,743	1,800	+19.6%
	472	534	595	560	718	704	714	755	587	748	649	—	915	1,049	1,189	1,179	1,137	1,109	1,024	1,077	1,138	1,173	1,260	1,230	1,311	+15.2%
Operating profit	413	298	264	328	436	377	349	348	270	297	290	—	294	324	356	359	264	297	360	348	368	314	435	513	489	+33.1%
OPM %	46.7%	35.8%	30.7%	36.9%	37.8%	34.9%	32.8%	31.6%	31.5%	28.4%	30.9%	—	24.3%	23.6%	23.1%	23.3%	18.9%	21.1%	26.0%	24.4%	24.4%	21.1%	25.7%	29.4%	27.2%	+2.8 pp
Other income	32.1	20.4	35.1	47.2	61.8	51.2	45.7	65.2	74.4	65.6	61.5	38.9	37.5	53.2	37.4	42.1	51.4	59.7	58.5	44.0	57.5	84.2	63.2	111	61.2	+6.4%
Interest	0.47	0.76	1.16	1.02	1.00	1.02	1.18	2.03	0.90	1.72	2.62	—	4.92	6.05	5.28	9.96	5.62	6.11	22.8	7.45	11.5	7.82	3.93	10.0	4.36	-62.1%
Depreciation	24.2	24.7	25.0	24.9	25.3	26.1	27.8	31.1	34.9	36.7	37.6	—	65.3	81.3	105	92.6	92.0	93.8	96.3	95.8	101	106	108	109	111	+10.1%
Profit before tax	420	293	273	349	472	401	366	381	309	324	311	111	261	290	283	298	218	257	299	288	313	284	362	506	435	+39.1%
Tax %	25.3%	25.2%	25.3%	25.4%	25.7%	24.6%	25.3%	24.9%	25.7%	25.6%	25.4%	—	25.7%	33.0%	32.2%	35.5%	34.1%	36.3%	31.6%	35.3%	31.1%	35.3%	27.8%	27.5%	27.1%	-4.0 pp
Net profit	314	219	204	260	351	302	273	286	229	241	232	78.7	194	194	192	192	144	164	205	187	215	184	261	367	317	+47.1%
EPS (₹)	20.24	14.12	12.83	15.93	21.41	18.37	16.62	17.40	13.93	14.65	14.08	—	11.79	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.26	19.23	+47.0%

One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters

Revenue & net profit trend

last 20 quarters

RevenueNet profit

Revenue & net profit — Consolidated20 quarters

Segment results

Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.

Forensic checksauto-scanned from the filing

Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.

How results moved the priceEOD reaction on the session the market could trade the filing

Avg absolute result-day move ±7.2%· EPS surprise: no estimates source· 1 earlier quarter has no dated filing on record

Q1'27filed Mon 10 Aug 16:19 · first tradeable session Tue 11 Auggap +6.7%close +9.6%

Q4'26filed Fri 15 May 21:09 · first tradeable session Mon 18 Maygap +13.6%close +15.4%

Q3'26filed Wed 28 Jan 17:44 · first tradeable session Thu 29 Jangap +8.0%close +6.5%

Q2'26filed Mon 3 Nov 16:34 · first tradeable session Tue 4 Novgap +0.4%close −3.1%

Q1'26filed Tue 5 Aug 16:25 · first tradeable session Wed 6 Auggap +2.8%close −0.4%

Q4'25filed Tue 20 May 21:55 · first tradeable session Wed 21 Maygap −0.6%close +4.9%

Q3'25filed Mon 3 Feb 17:22 · first tradeable session Tue 4 Febgap −0.3%close −3.7%

Q2'25filed Mon 4 Nov 17:38 · first tradeable session Tue 5 Novgap −0.6%close +13.8%

Q1'25filed Tue 6 Aug 17:01 · first tradeable session Wed 7 Auggap −4.6%close −3.8%

Q4'24filed Wed 22 May 17:41 · first tradeable session Thu 23 Maygap +6.5%close +5.0%

Q3'24filed Wed 14 Feb 16:19 · first tradeable session Thu 15 Febgap −1.5%close −2.7%

Q2'24filed Mon 6 Nov 16:18 · first tradeable session Tue 7 Novgap +4.5%close +5.0%

Q1'24filed Mon 7 Aug 16:18 · first tradeable session Tue 8 Auggap +11.7%close +20.0%

Q4'23filed Thu 18 May 17:26 · first tradeable session Fri 19 Maygap −12.9%close −20.0%

Q3'23filed Mon 23 Jan 16:12 · first tradeable session Tue 24 Jangap −1.9%close −1.5%

Q2'23filed Wed 26 Oct 15:46 · first tradeable session Thu 27 Octgap −5.0%close −14.6%

Q1'23filed Wed 20 Jul 16:02 · first tradeable session Thu 21 Julgap −7.4%close −5.8%

Q4'22filed Thu 19 May 16:08 · first tradeable session Fri 20 Maygap +0.4%close −1.1%

Q3'22filed Fri 21 Jan 15:40 · first tradeable session Mon 24 Jangap −0.6%close −7.4%

Q2'22filed Fri 22 Oct 15:44 · first tradeable session Mon 25 Octgap −0.4%close +0.9%

PeriodQ1 FY26-27BasisConsolidatedFiledAug 11, 2026Qualityaudited

Frequently Asked Questions

What is Gland Pharma Limited's latest revenue?: Gland Pharma Limited reported revenue of ₹6,431 Cr in its latest annual results, per the filed results.
What is Gland Pharma Limited's latest net profit?: Gland Pharma Limited reported net profit of ₹1,027 Cr in its latest annual results, per the filed results.
What is Gland Pharma Limited's return on equity?: Gland Pharma Limited posted ROE of 10.9% and ROCE of 15.7% for its latest annual results, computed from filed statements.
What is Gland Pharma Limited's operating margin?: Gland Pharma Limited's operating margin was 23.3% in its latest annual results, derived from filed operating expenses.
How much did Gland Pharma Limited's revenue grow year-on-year?: Gland Pharma Limited's revenue changed 14.5% year-on-year in its latest annual results, per the filed results.